- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05295316
Risk Factors of Primary Fibromyalgia
March 24, 2022 updated by: Carolina Lavazza, Studio Osteopatico Busto Arsizio
Risk Factors Recognition of Primary Fibromyalgia: a Case-control Study
Fibromyalgia (FM) is a condition with a different non-specific symptoms which lead to a difficult diagnosis.
Study suggests that osteopathy can help in improving FM symptoms, nevertheless, it can be difficult to identify which patients may benefit.
The knowledge of FM risk factor can be useful tool for osteopaths and other clinician to implement a targeted, fast and multidisciplinary treatment protocol for those kind of patient.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
94
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Novara, Italy
- OsteoMedical
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Probability Sample
Study Population
Female patients with or without fibromyalgia
Description
Inclusion Criteria:
- female patients
- Patient from Piedmont
- age between 20 and 65 years old
- inform consent
- for case group primary or secondary fibromyalgia
Exclusion Criteria:
- systemic or rheumatic or neoplastic diseases
- for control group the presence of primary or secondary fibromyalgia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Fibromyalgia
FM group was recruited at AMaR (rheumatic patients association of Piedmont) and the diagnosis of primary fibromyalgia was confirmed by the referring rheumatologist of the AMaR association.
|
Evaluation of stress factor as risk factor for fibromyalgia development
|
Control
The control group was recruited in the same geographic area as the FM participant.
The general practitioner of each individual patient certified the subject's state of good health.
|
Evaluation of stress factor as risk factor for fibromyalgia development
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of 29 stressing events
Time Frame: 1 year
|
The LSC-R questionnaire was used to evaluate the incidence of each stressor event
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Carolina Lavazza, MSc, Accademia Italiana Medicina Osteopatica
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 12, 2020
Primary Completion (Actual)
February 3, 2021
Study Completion (Actual)
October 18, 2021
Study Registration Dates
First Submitted
March 11, 2022
First Submitted That Met QC Criteria
March 24, 2022
First Posted (Actual)
March 25, 2022
Study Record Updates
Last Update Posted (Actual)
March 25, 2022
Last Update Submitted That Met QC Criteria
March 24, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 230176
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia
-
University of AberdeenCompletedFibromyalgia | Fibromyalgia, Primary | Fibromyalgia, SecondaryUnited Kingdom
-
Eli Lilly and CompanyCompletedFibromyalgia, Primary | Fibromyalgia, SecondaryMexico
-
Rasmia ElgoharyNot yet recruiting
-
Spaulding Rehabilitation HospitalNot yet recruiting
-
Cairo UniversityNot yet recruiting
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
University of UtahTerminated
-
State University of New York - Upstate Medical...CompletedFibromyalgia, PrimaryUnited States
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel